This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Musk, OpenAI battle over remedy claims in forthcoming US trial

By Mike Swift ( April 13, 2026, 17:40 GMT | Official Statement) -- MLex Summary: Two weeks before the scheduled start of a trial between Elon Musk, OpenAI and Microsoft over OpenAI's conversion to for-profit status, Musk and OpenAI battled in a pair of weekend court filings about whether Musk's goal is "injecting chaos" into the case. Musk's "Amended Notice of Remedies seeks to upend the expectations of the parties and the Court, no doubt in recognition that Musk’s claims are neither plausible nor appealing — and with the apparent objectives of sandbagging the defendants and injecting chaos into the proceedings," OpenAI said. Musk responded that returning "the OpenAI charity to its rightful role and ensuring that its governance is never again corrupted are not novel requests in this case, and Plaintiff’s reiteration of those requests in his Amended Notice is not prejudicial to anyone."See attached documents....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login